Roth Mkm Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

Roth Mkm reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.

GANX has been the topic of several other reports. Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $7.25.

Gain Therapeutics Trading Up 1.3 %

Shares of GANX stock opened at $1.59 on Tuesday. The business’s fifty day moving average price is $2.03 and its 200 day moving average price is $1.61. The firm has a market capitalization of $42.17 million, a PE ratio of -1.45 and a beta of 0.21. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a 1-year low of $0.89 and a 1-year high of $5.33.

Institutional Trading of Gain Therapeutics

A number of large investors have recently made changes to their positions in the stock. Hohimer Wealth Management LLC acquired a new stake in shares of Gain Therapeutics in the second quarter worth approximately $422,000. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares during the last quarter. Finally, Warberg Asset Management LLC acquired a new position in Gain Therapeutics in the second quarter valued at $66,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.